Atlas Trials

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Clinical trial NCT03987698 · UNKNOWN

Trial details

NCT number
NCT03987698
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Start date
2019-06-01
Primary completion
2022-06-01
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.